Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Allied Biotech Corp (1780) AI Stock Analysis

TW:1780

Allied Biotech Corp

(TPEx:1780)

Select Model
Rating:72Outperform
Price Target:TWD 26.00â–²(9.70% Upside)
Action:initiatedcoverage
Date:11/10/26

Strong financial performance from solid cash flows and reduced leverage is the main positive driver, reinforced by attractive valuation; weak technical momentum with price below moving averages and negative MACD limits upside.

Positive Factors
Improving ProfitabilityHigher revenue, margins, and net income indicate improving operating performance and stronger earnings power. If maintained, this progress can support internal investment, strengthen resilience, and provide a more durable foundation for shareholder returns over the next several quarters.
Negative Factors
Uneven Margin PerformanceThe margin pattern shows that recent profitability has not yet demonstrated consistent durability across the cycle. A return toward weaker historical margins could limit earnings growth, reduce reinvestment capacity, and make future results more variable than the latest year suggests.

Allied Biotech Corp (1780) vs. SPDR S&P 500 ETF (SPY)

-20%0%20%40%60%80%TW:1780+20.46%SPY+14.30%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
TWD 2.59B
Dividend Yield
5.27%
Average Volume (3M)
76.53K
Price to Earnings (P/E)
8.0
Beta (1Y)
0.28
Revenue Growth
―
EPS Growth
―
Country
TW
Employees
40
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Allied Biotech Corp Business Overview & Revenue Model

Company Description

Allied Biotech Corporation operates as a global producer and supplier specializing in carotenoids. The company's diverse product portfolio features key carotenoids such as: Beta-Carotene, known for imparting vibrant yellow to reddish-orange hues acro...

Allied Biotech Corp Financial Statement Overview

Summary

Robust cash generation with operating cash flow at 217 million and 84.5% conversion rate, plus improved balance sheet with debt-to-equity reduced to 0.59 and steady revenue growth to 849 million.

Income Statement

76Positive

Balance Sheet

81Very Positive

Cash Flow

85Very Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue916.48M849.51M806.92M720.43M716.75M676.76M
Gross Profit363.14M308.61M258.38M246.44M271.05M258.05M
EBITDA217.64M242.44M205.93M204.79M270.55M94.06M
Net Income285.89M129.46M100.94M97.41M146.74M13.04M
Balance Sheet
Total Assets2.56B2.09B2.26B2.08B2.18B2.44B
Cash, Cash Equivalents and Short-Term Investments1.22B853.91M987.24M724.77M793.00M1.14B
Total Debt752.48M733.52M955.38M796.61M838.04M1.25B
Total Liabilities1.04B857.19M1.06B910.12M999.40M1.36B
Stockholders Equity1.52B1.23B1.20B1.17B1.18B1.08B
Cash Flow
Free Cash Flow171.66M183.55M196.98M89.71M109.62M22.44M
Operating Cash Flow202.53M217.13M223.79M137.62M164.27M72.43M
Investing Cash Flow-52.25M-89.49M70.55M-40.94M219.02M-180.94M
Financing Cash Flow54.77M-319.33M64.94M-158.33M-462.00M164.24M

Allied Biotech Corp Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

TW:1780 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TW:1780TW:178072OutperformTWD 2.59B8.03―5.27%――
TW:1733TW:173363NeutralTWD 2.85B15.05―4.55%-5.22%22.94%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TW:1762TW:176240UnderperformTWD 2.39B-35.22―0.62%-20.25%81.66%
TW:6657TW:665738UnderperformTWD 2.69B-8.88――-4.36%1.97%

* General Sector Average

Performance Comparison

-25%0%25%50%TW:1780TW:1733TW:1762TW:6657TW:6918TW:6955Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TW:1780 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TW:1780Allied Biotech Corp23.703.5917.86%
TW:1733Apex Biotechnology Corp.28.60-0.81-2.76%
TW:1762Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A32.757.5529.96%
TW:6657Energenesis Biomedical Co., Ltd.30.00-11.55-27.80%
TW:6918A Plus Biotechnology Co Ltd74.90-7.83-9.46%
TW:6955Bonraybio Co. Ltd.87.30-46.17-34.59%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026